Multitude Therapeutics (MTX) is a spinoff company from the Therapeutics division of Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing antibody-drug conjugates (ADC), bispecific antibodies, and CAR-Ts for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.